### Population 2018

<table>
<thead>
<tr>
<th>Estimated of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>301 (215–400)</td>
<td>520 (373–691)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>177 (127–235)</td>
<td>306 (219–406)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>11 (7.2–16)</td>
<td>19 (12–28)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>21 (20–23)</td>
<td>37 (35–39)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>42 (30–57)</td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

### Estimates of TB burden, 2018

- % tested with rapid diagnostics at time of diagnosis: 71%
- % with known HIV status: 90%
- % pulmonary: 89%
- % bacteriologically confirmed: 70%
- % children aged 0-14 years: 7%
- % women: 37%
- % men: 56%

### Total cases notified

- 227,999

### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 92%
  - New cases: 92%
  - Previously treated cases: 94%

### Laboratory-confirmed cases

- MDR/RR-TB: 13,199
- XDR-TB: 553

### Patients started on treatment

- MDR/RR-TB: 9,558
- XDR-TB: 539

### Treatment success rate and cohort size

- New and relapse cases registered in 2017: 77% (240,332)
- Previously treated cases, excluding relapse, registered in 2017: 59% (6,508)
- HIV-positive TB cases registered in 2017: 75% (134,672)
- MDR/RR-TB cases started on second-line treatment in 2016: 54% (11,159)
- XDR-TB cases started on second-line treatment in 2016: 58% (601)

### TB preventive treatment, 2018

- 65%
- 59% (54–65)

### TB financing, 2019

- National TB budget (US$ millions): 240
- Funding source: 87% domestic, 13% international, 0% unfunded

---

* Ranges represent uncertainty intervals
* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
* Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

**Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.**

**Generated: 2020-03-11  Data: www.who.int/tb/data**